Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Postoperative ctDNA in Resectable Esophageal Squamous Cell Carcinoma: From Molecular Residual Disease Detection Toward Risk-Adapted Adjuvant Therapy and Surveillance.

Created on 07 Nov 2026

Authors

Tamotsu Sagawa, Masahiro Hirakawa, Hiroyuki Nagashima, Koshi Fujikawa

Published in

Journal of gastrointestinal cancer. Volume 57. Issue 1. Nov 06, 2026. Epub Nov 06, 2026.

Abstract

Postoperative circulating tumor DNA (ctDNA) is emerging as a marker of molecular residual disease (MRD) after curative-intent treatment for esophageal squamous cell carcinoma (ESCC). This review evaluates its ability to refine recurrence-risk assessment beyond pathological response and its potential role in guiding adjuvant therapy and surveillance.
A structured narrative review of studies evaluating perioperative and postoperative ctDNA in resectable ESCC was conducted using PubMed/MEDLINE through August 17, 2026, supplemented by citation tracking and clinical trial registry searches. Evidence was synthesized across treatment pathways, assay platforms, and postoperative management settings.
Across ESCC cohorts using digital PCR, fixed next-generation sequencing panels, and personalized tumor-informed assays, postoperative ctDNA positivity consistently identifies patients at increased risk of recurrence, although estimates remain imprecise in small cohorts. Serial testing can detect molecular relapse months before radiographic recurrence. Integrated pathology-MRD models demonstrate additional risk stratification within both pathological complete response and non-completeresponse groups. Observational findings suggest, but do not establish, that MRD-positive patients may derive greater benefit from adjuvant immunotherapy. Conversely, MRD negativity alone does not justify omission of indicated adjuvant treatment.
Postoperative ctDNA provides complementary molecular risk information beyond conventional pathology in resectable ESCC. However, prospective MRD-guided trials are required before postoperative treatment or surveillance strategies can be routinely modified on the basis of ctDNA results alone.

PMID:
42993440
Bibliographic data and abstract were imported from PubMed on 07 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement